Introduction: Besides its critical role in metabolic
and the selectin family (P-selectin, E-selectin), which are upregulated during atherogenesis [6] and elevated in type 2 diabetes [7] . A growing body of evidence suggests that inflammatory pathways could also be involved in microvascular damage, participating in the pathogenesis of diabetes complications, such as retinopathy and nephropathy [8] [9] .
Thiazolidinediones (TZDs) can reduce CD40 ligand (CD40L) serum levels, suggesting an antiinflammatory mechanism [10] and a possible modulation of platelet aggregation [11] . TZDs regulate not only the activity of genes involved in glucidic or lipidic metabolism, but also that of genes regulating the inflammatory response of endothelium, vascular smooth muscle cells, T-cells, and monocytes/macrophages [7] .
Furthermore, peroxisome proliferator-activated receptor (PPAR) activation reduces the production of inflammatory cytokines and the expression and release of metallo-proteases from macrophages [12] , while in animal models an effect of TZDs on oxidative stress production has also been reported [13, 14] .
The anti-inflammatory effect of TZDs in patients with type 2 diabetes has been reported in several trials [14] [15] [16] [17] [18] [19] [20] . However, all these studies were designed with different endpoints (usually glycemic control), and the anti-inflammatory actions of TZD were observed only as a secondary outcome. To our knowledge, this is the first trial to date designed to assess the effect of repeated doses of the TZD, pioglitazone, on inflammation, having CRP as its principal endpoint. Pioglitazone was studied as monotherapy in order to avoid the possible interference of other drugs; metformin was chosen as a comparator because it is not a TZD agent but it does have a profile of action on blood glucose and insulin resistance that is as similar as possible to that of pioglitazone. group; P = 0.36). Pioglitazone treatment was also found to be associated with a statistically significant increase in total cholesterol levels (+10 mg/dL in the pioglitazone arm, -3 mg/dL in the metformin arm; P = 0.05) and a decrease in liver enzyme levels. Study drugs were titrated to higher doses when
Conclusions

MATERIALS AND METHODS
Study Design
The study was designed as a 16- 
Study Participants
The study was conducted in 10 diabetes clinics.
Patients of either sex were enrolled, provided they met all the following inclusion criteria: diagnosis of type 2 diabetes mellitus (defined using the American Diabetes Association criteria [21] 
Sample Size
The sample size calculation was based on the primary objective of demonstrating a reduction in CRP levels induced by pioglitazone as opposed to metformin. Based on previous evidence on troglitazone [22] , the sample size was calculated to detect a reduction of 3 mg/L in CRP levels in patients treated with pioglitazone compared to those receiving metformin, with a statistical power of 90% (α = 0.05), and assuming a standard deviation in CRP levels of 3 mg/L. Given these assumptions, a minimum of 20 subjects in each arm were needed. It was planned to enroll at least 50 individuals to allow for a 20% dropout rate.
Statistical Methods
Baseline demographic and background data were summarized as percentages for Within-group changes were tested using the paired t-test or the signed rank Wilcoxon test. For the assessment of differences between treatment groups with respect to primary and secondary endpoints, a repeated measures analysis of variance (ANOVA) of the change from baseline to the end of the study was applied using PROC MIXED software (SAS, release 9.1; SAS Institute, Cary, NC, USA).
Continuous variables with substantial
deviations from the normality assumption were mathematically transformed.
Statistical analyses were performed on the intention-to-treat population, i.e., all randomized patients who received at least one dose of study medication and who completed at least 8 weeks of treatment.
RESULTS
Overall, 67 patients were initially identified, of whom 9 were not randomized ( Table 1 and show that the two groups were well matched for all the variables investigated. Results relative to all efficacy and safety laboratory parameters are reported in Table 2 .
Primary Efficacy Variable: CRP
A statistically significant decrease from baseline to week 16 was observed in the CRP levels of 
Secondary Efficacy Variables
A statistically significant decrease from baseline to week 16 in E-selectin levels (P < 0.05) was observed in patients treated with pioglitazone compared to no changes in patients treated with metformin.
The comparison between treatments showed a statistically significant difference in favor of pioglitazone for E-selectin levels (P = 0.01).
No statistically significant changes in markers of platelet activation and thrombogenesis, or nitrotyrosine levels, were observed with either treatment. with metformin was of severe intensity, but was not considered to be related to study drug.
Fig. 1 Study ow diagram
Six patients, four treated with pioglitazone and two with metformin, discontinued the study due to AEs. Causes of early discontinuations in patients treated with pioglitazone were hypoglycemia in two patients, general discomfort, vomiting, and diarrhea in one patient, and abdominal pain in another patient.
In the metformin group, myocardial ischemia in one patient and flatulence in another were responsible for discontinuations.
Laboratory Safety Parameters
The results of hematology tests at baseline and The comparison between treatments showed a statistically significant difference in favor of pioglitazone for levels of ALT (P < 0.0001), AST (P = 0.003), and γGT (P < 0.0001).
DISCUSSION
It is increasingly recognized that markers of vascular inflammation play a role in the pathogenesis of type 2 diabetes, insulin resistance, and atherosclerosis [11, 23] ; CRP in particular is an independent predictor of both type 2 diabetes and CVD [4, 24] . In fact, in comparisons with sulfonylureas, the TZD, pioglitazone, has shown beneficial effects on intima-media thickness [28] and on the progression of coronary atherosclerosis [29] , which are evident after a relatively short follow-up. Based on these observations, it can be speculated that the reduction in major cardiovascular events reported in the PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) study [30] and confirmed by meta-analyses, including all available pioglitazone trials [31] [32] , is partly due to some extraglycemic action of the drug. risk has been reported [33] . In the present study, the authors were able to show that in diabetic patients at low risk for cardiovascular disease, this beneficial (CRP-lowering) effect was superior to that achieved with metformin.
The lack of any significant effect of treatment on platelet activity and on markers of platelet activation and thrombogenesis is inconsistent with previous studies [11, 34] . This result could be explained by the fact that in the present trial, the patients enrolled were drug-naïve and they had relatively moderate hyperglycemia. It is possible that some of the previously described benefits of TZD treatment on these parameters were related to the improvement in blood glucose in patients with a greater degree of impairment in metabolic control.
In this study, pioglitazone treatment was found to be associated with a statistically significant increase in total cholesterol and HDL-C levels. It is well recognized that pioglitazone positively affects the lipid profile by increasing HDL-C and reducing trigycerides.
The effect on total cholesterol is less clear but a recent meta-analysis reported that treatment with this drug was associated with a significant reduction in total cholesterol [35] . Furthermore, it is known that pioglitazone modifies LDL particle size, reducing its atherogenic effects [36] .
Recently, a post-hoc analysis of the PROactive study showed that the beneficial effect of pioglitazone on cardiovascular outcome was mainly due to an increase in HDL-C, rather than an amelioration of HbA 1c [37] .
In our study, pioglitazone treatment significantly decreased levels of liver enzymes. 
